Skip to main content

Drug Interactions between meropenem and teriflunomide

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

meropenem teriflunomide

Applies to: meropenem and teriflunomide

MONITOR: Coadministration with teriflunomide may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic anion transporter 3 (OAT3). The proposed mechanism, based on in vivo data, is decreased clearance due to teriflunomide-mediated inhibition of OAT3 transporter. Following repeated doses of teriflunomide, the mean Cmax and AUC of cefaclor, an OAT3 substrate, increased 1.43- and 1.54-fold, respectively.

MANAGEMENT: Caution is advised if teriflunomide is used concomitantly with drugs that are substrates of OAT3. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever teriflunomide is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.

References (3)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2012) "Product Information. Aubagio (teriflunomide)." Genzyme Corporation

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer